Please assess the completion status of the following clinical trial:

Trial Title: Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 - \< 65 years.~2. Histology verified according to the WHO classification and with CD20 positivity by immunhistochemistry or flow cytometry:~   * Diffuse large B-cell lymphomas with subgroups except posttransplantation-, Burkitt-like- and primary CNS lymphomas and cases with leptomeningeal lymphoma involvement. Morphologically discordant lymphomas (most often follicular lymphoma and diffuse large cell B-cell lymphoma in different biopsy specimens, e.g. lymphatic gland and bone marrow) and transformed lymphomas are not to be included.~  * Follicular lymphomas grade III The diagnosis made by the local pathologist of the participating centre will be accepted for registration~3. Patients in at least stage II with age adjusted IPI score of 2 or 3:~   Stage III /IV and elevated LDH and/or WHO performance status 2 - 3 Stage II and elevated LDH and WHO performance status 2 - 3.~4. Previously untreated.~5. Performance status \< 4 (Appendix 2).~6. Written informed consent~Exclusion Criteria:~1. Severe cardiac disease: cardiac function grade 3-4 (Appendix 2) or Left Ventricular Ejection Fraction (LVEF) \< 45% (based on MUGA scintigraphy or echo Doppler cardiography).~2. Impaired liver, renal or other organ function not caused by lymphoma, which will interfere with the treatment schedule.~3. Pregnancy.~4. Men and women of reproductive potential not agreeing to use an acceptable method of birth control during treatment and for six months after completion of treatment.~5. Patients with other severe medical problems and with an expected short survival for non-lymphoma reasons.~6. Known HIV positivity.~7. Present or previous cancer except basal cell carcinoma and cervical carcinoma in situ.~8. Uncontrolled infectious disease.~9. Psychiatric or mental disorder which make the patient unable to give an informed consent and/or adhere to the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Chemoimmunotherapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).